Answers are grounded in this paper and cite their sources.
Cellular therapy is entering a new phase in solid tumors. For dermato-oncology, this shift is no longer theoretical: tumor-infiltrating lymphocyte (TIL) therapy is approved in the United States, and PRAME-directed T cell receptor (TCR) T cells provide the leading receptor-defined benchmark for melanoma. Chimeric antigen receptor (CAR) T cell therapy has entered early-phase clinical evaluation for melanoma and cutaneous lymphomas, with ongoing trials targeting GD2, IL13Rα2, NG2, DLL3, and CD30. Early clinical findings support the feasibility of this approach, demonstrate CAR T cell trafficking to tumor sites, and indicate an acceptable safety profile. The clinical challenge is therefore not conceptual but translational: selecting sufficiently tumor-restricted surface antigens, overcoming antigen heterogeneity, improving trafficking and persistence, and combining CAR T cells rationally with checkpoint blockade, targeted therapy, radiotherapy, or oncolytic strategies. This article summarizes the current clinical landscape and proposes a practical path toward biomarker-selected, combination-ready CAR T cell trials in advanced skin cancer.
No takes yet. Share an insight, caveat, or question.
Uğur Uslu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: